Mental Health

COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office

PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers…

3 years ago

Sharecare reveals finalists in the 2023 Sharecare Awards

General public invited to vote for Sharing Care Award through June 16; winner announced live on stage at HLTH 2023…

3 years ago

Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp.

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “the Company”) (NASDAQ: LSDI), a…

3 years ago

Beckley Waves Establishes Ethics Council to Guide Industry Standards and Best Practices During Inaugural Summit of The World’s Leaders in Psychedelics

The New Ethics Council will Work Alongside Beckley Waves to set the Standard for Sustainable and Ethical Operations in the…

3 years ago

Solera Launches Streamlined Multi-Condition Management Platform for Employers to Increase Accountability While Reducing Costs

With Solera’s curated network of algorithmically matched digital health solutions, employers can reduce administrative burden and costs with a single…

3 years ago

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating…

3 years ago

Neuronetics Announces Increased TMS Access Through BlueCross BlueShield Of Michigan

Lower Medication Requirement Helps Depression Patients Obtain Treatment SoonerMALVERN, Pa., May 26, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM),…

3 years ago

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD)

Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive…

3 years ago

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational…

3 years ago

New Depression Barometer Survey Shows Patients Are Stopping Treatment Due to Dissatisfaction

Lowest satisfaction among medication users, highest for users of non-drug solution TMS Therapy NeuroStar Depression Barometer Infographic FocalData survey results…

3 years ago